Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | PDE1A | P54750 | 2/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775879 | 0.85 | OPRM1 (0.33) | SMN1; SMN2CASP6OPRM1MPO | |
| SCHEMBL1946869 | 0.84 | KDM4E (0.56) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL1958856 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL1959860 | 0.77 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL562680 | 0.77 | MAPK10 (0.47) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL1958079 | 0.76 | KDM4E (0.54) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL1958096 | 0.75 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL1958334 | 0.74 | L3MBTL1 (0.50) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL1959286 | 0.73 | CASP6 (0.61) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL1960677 | 0.72 | KDM4E (0.50) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236951-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2012-08-07 | — | — | US | disclosed |
| EP-1499613-B1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-19 | — | — | EP | disclosed |
| EP-2332541-A1 | Use of thioxanthine derivatives as MPO inhibitors | AstraZeneca AB (SE) | 2011-06-15 | — | — | EP | disclosed |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-7425560-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | MPO, XDH, EPX | SMN1; SMN2 1607/4885ALDH1A1 178/4885KDM4E 3438/4885 |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | MPO, XDH, EPX | SMN1; SMN2 1607/4885ALDH1A1 178/4885KDM4E 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.